ASND - Ascendis Pharma AS Profit before interest, taxes and amortization

Brandmark of Ascendis Pharma (ASND)

Ascendis Pharma A/S is implementing ESG standards to reduce its environmental footprint and ensure compliance with bioethics. The company's EBITDA reflects its cash generation dynamics, where 145.99 determines the current status of the parameter. Business efficiency is based on the outsourcing of clinical trials and distribution. Additionally, the robotization of protein compound synthesis via the TransCon system minimizes laboratory errors.

Ascendis Pharma Inc. - ASND Operating profit EBITDA (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for Ascendis Pharma (ASND)

- current quotes and average value forecast:
Stock Quotes Ascendis|ASND - Analyst Consensus Forecast
- market capitalization statistics:
Market Value Ascendis Pharma|ASND - Real Price to Acquire Entire Company
- book capitalization data:
Book Price of a Share Ascendis Pharma|ASND - Book Capitalization|Market Capitalization to Book Value Ratio ascendispharma.com|ASND - Company Total Assets
- company total debt and liquidity indicators:
Debt to Equity Ascendis Pharma A/S|ASND - Long-Term Debt to Equity|Current Liabilities to Capital Ascendis Pharma AS|ASND - Company Debts|Debt to Book Capitalization Ratio Ascendis Pharma|ASND - Company Long-Term Debts|Short-Term Debt Volume Ascendis Pharma|Interim Coverage Ratio ascendispharma.com
- financial results and valuation multiples details:
ASND - Company Net Income|Future Profit Ascendis Pharma A/S|ASND - P/E Multiple|Forward P/E Multiple ascendispharma.com|ASND - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Ascendis Pharma|ASND - Operating profit EBITDA|Net earnings per share for the last 12 months Ascendis Pharma|ASND - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months ascendispharma.com|ASND - Earnings per share growth in current year|Projected earnings per share growth rate for next year Ascendis Pharma A/S
Analysis of all company metrics:Ascendis (ASND)
Manufactured products of Ascendis Pharma A/S

The indicator calculates the daily cash flow from operating activities, excluding non-cash accounting adjustments from previous periods. This metric captures real operating income, allowing for the timely detection of declining demand and the avoidance of capital freezes. For Ascendis Pharma A/S (ASND), this reflects the commercialization efficiency of the TransCon platform and the monetization of long-acting drugs. Revenue dynamics directly impact the EBITDA as of the current date. A decline in this line signals fundamental business risks.

Who Ascendis Pharma A/S competes with

MDGL - Operating profit before deduction of amortization|Corcept Therapeutics - Operating profit EBITDA|Profit before interest, taxes and amortization rhythmtx.com|AKRO (Akero) - Operating profit before deduction of amortization|MTSR: Company profit before taxes, interest and amortization|MLTX (MoonLake Pharma) - Operating profit EBITDA|Operating profit EBITDA Crinetics Corp|Operating profit EBITDA NAMS|Profit before payment of interest, taxes and amortization SLNO (soleno.life)|Profit before payment of interest, taxes and amortization Amicus Therapeutics, Inc. FOLD|89bio Inc (ETNB) - Profit before interest, taxes and amortization|AGIO - Profit before payment of interest, taxes and amortization|GPCR: Profit before payment of interest, taxes and amortization|MDXG: Operating profit EBITDA|RZLT - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Lexicon Pharmaceuticals, Inc.|MBX Biosciences, Inc. (MBX) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Altimmune Corp (ALT)|Operating profit before deduction of amortization Aardvark Pharma AARD|Operating profit EBITDA SGMT (Sagimet Biosciences)|Operating profit EBITDA bioagelabs.com BIOA|BMEA - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Quince Therapeutics QNCX|GUTS: Operating profit EBITDA|Operating profit before deduction of amortization vTv Therapeutics|ATPC (Agape ATP Corp) - Operating profit EBITDA|Profit before interest, taxes and amortization Pluri Inc PLUR|Profit before payment of interest, taxes and amortization Synlogic, Inc. (SYBX)|Lipocine Inc - Operating profit before amortization|Operating profit EBITDA MTNB (Matinas BioPharma Holdings)|SPRB: Operating profit before amortization|Galecto, Inc. - Operating profit EBITDA|Operating income before deduction of amortization carmellrx.com CTCX|Lumos Pharma (LUMO) - Profit before payment of interest, taxes and amortization|ONVO - Operating income before deduction of amortization|Operating profit before deduction of amortization RDUS